Guggenheim Reiterates Buy Rating on Soleno Therapeutics

Summary

Guggenheim has reaffirmed a ‘buy’ rating for Soleno Therapeutics (SLNO) with a target price of $106.00, indicating a potential upside of 52.35%. Other analysts have issued positive ratings, with HC Wainwright setting a target of $110.00 and Robert W. Baird at $121.00. Soleno’s stock is currently trading at $69.58, with a market cap of $3.70 billion. The company reported a quarterly EPS of ($0.09), surpassing estimates, and has a strong institutional ownership of 97.42%.Market Beat

Impact Analysis

The event is classified at the company level, as it revolves around Soleno Therapeutics and analyst ratings for its stock. The reaffirmation of a ‘buy’ rating by Guggenheim and other positive ratings from analysts suggest strong investor confidence in Soleno’s future prospects. The target price set by Guggenheim implies a potential upside of over 52%, which may attract more investors and positively influence the stock’s price movement. Given Soleno’s strong institutional ownership and its recent EPS surpassing estimates, these factors could further enhance investor sentiment.Market Beat The analysis of stock price movements in recent trading cycles, as referenced, supports further examination of Soleno’s performance in the market, providing insights into fluctuations and stability. This presents investment opportunities for those looking to capitalize on potential stock appreciation. However, investors should remain aware of any market volatility or broader economic influences that could affect stock performance.